Sadeghi Mahsa, Mobayen Mohammadreza, Yaghubi Kalurazi Tofigh, Mehrdad Zahra, Gaskarei Mohammadamin Khajavi, Moghadam Sina Kamrani, Sedigh Ebrahim-Saraie Hadi, Hasannejad-Bibalan Meysam
Burn and Regenerative Medicine Research Center Guilan University of Medical Sciences Rasht Iran.
Department of Microbiology, School of Medicine Guilan University of Medical Sciences Rasht Iran.
Health Sci Rep. 2025 Jul 18;8(7):e71054. doi: 10.1002/hsr2.71054. eCollection 2025 Jul.
() is a major cause of burn wound infections, posing a significant challenge due to its increasing antibiotic resistance. This study evaluated the prevalence and antibiotic resistance patterns of isolates from burn patients admitted to a referral burn center in Northern Iran over 3 years (March 2018-March 2021).
A retrospective cross-sectional study was conducted on 535 samples collected from burn patients. isolates were identified using standard microbiological methods and tested for susceptibility to various antibiotics through the disc diffusion method. Data analysis involved descriptive statistics to assess the prevalence and resistance patterns of the isolates.
accounted for 36.1% (193/535) of bacterial isolates. The annual prevalence of varied from 19.6% to 44.4%, with the highest frequency observed among patients with 26%-50% total body surface area burns. Skin and soft tissue infections were the most common source (75.1%), followed by bloodstream infections (15%). Notably, 62.7% of isolates originated from intensive care unit (ICU) patients. High resistance was observed against ceftazidime (80%), ciprofloxacin (77.2%), imipenem (76.6%), and meropenem (76.1%). Conversely, amikacin (78.2%) and gentamicin (45%) exhibited the highest susceptibility.
The findings indicate a high prevalence of with DTR, highlighting the need for stricter antibiotic stewardship and alternative treatment options. While amikacin showed higher susceptibility in our study, the recent CLSI 2023 guidelines suggest its use should be limited to urine isolates. In light of these updated recommendations, the use of aminoglycosides in treating infections requires cautious evaluation. Further multicenter studies with larger sample sizes are warranted to generalize these findings.
（某病菌名称未给出）是烧伤创面感染的主要原因，因其抗生素耐药性不断增加而构成重大挑战。本研究评估了伊朗北部一家转诊烧伤中心3年（2018年3月至2021年3月）收治的烧伤患者中该病菌的流行情况及抗生素耐药模式。
对从烧伤患者收集的535份样本进行回顾性横断面研究。使用标准微生物学方法鉴定该病菌，并通过纸片扩散法检测其对各种抗生素的敏感性。数据分析采用描述性统计来评估病菌的流行情况和耐药模式。
该病菌占细菌分离株的36.1%（193/535）。该病菌的年流行率在19.6%至44.4%之间变化，在全身表面积烧伤26%-50%的患者中观察到的频率最高。皮肤和软组织感染是最常见的来源（75.1%），其次是血流感染（15%）。值得注意的是，62.7%的分离株来自重症监护病房（ICU）患者。观察到对头孢他啶（80%）、环丙沙星（77.2%）、亚胺培南（76.6%）和美罗培南（76.1%）的高耐药性。相反，阿米卡星（78.2%）和庆大霉素（45%）表现出最高的敏感性。
研究结果表明具有耐多药的该病菌流行率很高，突出了更严格的抗生素管理和替代治疗选择的必要性。虽然阿米卡星在我们的研究中显示出较高的敏感性，但最近的CLSI 2023指南建议其使用应限于尿液分离株。鉴于这些更新的建议，在治疗该病菌感染中使用氨基糖苷类药物需要谨慎评估。有必要进行进一步的大样本多中心研究以推广这些发现。
